EntryPoint Capital LLC Has $494,000 Position in AbCellera Biologics Inc. (NASDAQ:ABCL)

EntryPoint Capital LLC increased its stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL) by 44.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 168,682 shares of the company’s stock after buying an additional 51,524 shares during the quarter. EntryPoint Capital LLC’s holdings in AbCellera Biologics were worth $494,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Walleye Capital LLC bought a new stake in shares of AbCellera Biologics during the third quarter worth $668,000. JPMorgan Chase & Co. increased its holdings in AbCellera Biologics by 6.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 355,747 shares of the company’s stock worth $925,000 after purchasing an additional 21,483 shares in the last quarter. Moloney Securities Asset Management LLC bought a new position in AbCellera Biologics in the fourth quarter valued at about $265,000. State Street Corp boosted its stake in shares of AbCellera Biologics by 1.5% during the third quarter. State Street Corp now owns 323,229 shares of the company’s stock valued at $840,000 after purchasing an additional 4,679 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of AbCellera Biologics by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 62,629 shares of the company’s stock worth $184,000 after purchasing an additional 5,955 shares during the last quarter. Institutional investors own 61.42% of the company’s stock.

AbCellera Biologics Price Performance

Shares of ABCL stock opened at $2.53 on Wednesday. The stock has a market capitalization of $753.91 million, a PE ratio of -4.15 and a beta of 0.45. The business’s 50 day simple moving average is $2.89 and its 200 day simple moving average is $2.82. AbCellera Biologics Inc. has a one year low of $2.11 and a one year high of $4.75.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ABCL shares. Stifel Nicolaus cut their target price on shares of AbCellera Biologics from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Benchmark reissued a “hold” rating on shares of AbCellera Biologics in a research note on Monday, March 3rd. Finally, KeyCorp lowered their target price on AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th.

AbCellera Biologics Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.